JN.1 is now dominant in the U.S., though the CDC said there is no evidence the subvariant presents a higher public health risk than other circulating variants. Nationwide, the subvariant accounts for an estimated 44% of COVID-19 cases, up from just 7.5% in the two-week period ending Nov. 25, CDC data shows.
The subvariant’s cumulative prevalence — which represents a ratio of sequences containing JN.1 to all sequences collected in the U.S. since the subvariant wasfirst detected Sept. 14 — is 2%, according to outbreak.info.
Below is a breakdown of JN.1 prevalence by state, based on the most recent data available from outbreak.info. As COVID-19 sequencing is not a random sample of mutations, the data represents outbreak.info’s best estimates of the subvariant’s prevalence, as opposed to true prevalence.
Note: Becker’s calculated each state’s estimated cumulative JN.1 presence using sequencing data from outbreak.info. Figures are rounded to the nearest thousands.
|
State |
JN.1 positive samples |
Total sequences sampled |
Estimated cumulative prevalence (%) |
|
Arkansas |
2 |
8 |
0.25 |
|
District of Columbia |
1 |
5 |
0.2 |
|
Massachusetts |
10 |
63 |
0.16 |
|
Iowa |
64 |
418 |
0.15 |
|
New York |
287 |
2094 |
0.14 |
|
Florida |
17 |
134 |
0.13 |
|
New Jersey |
83 |
769 |
0.11 |
|
Nevada |
18 |
170 |
0.11 |
|
New Hampshire |
1 |
11 |
0.09 |
|
Washington |
14 |
163 |
0.09 |
|
Kentucky |
2 |
29 |
0.07 |
|
Maryland |
8 |
118 |
0.07 |
|
Illinois |
36 |
581 |
0.06 |
|
Virginia |
31 |
512 |
0.06 |
|
Wyoming |
3 |
50 |
0.06 |
|
Pennsylvania |
15 |
277 |
0.05 |
|
Delaware |
9 |
170 |
0.05 |
|
Montana |
1 |
22 |
0.05 |
|
Arizona |
24 |
534 |
0.04 |
|
Georgia |
3 |
71 |
0.04 |
|
California |
70 |
2,113 |
0.03 |
|
North Dakota |
1 |
32 |
0.03 |
|
Utah |
18 |
600 |
0.03 |
|
South Carolina |
1 |
39 |
0.03 |
|
North Carolina |
5 |
196 |
0.03 |
|
Connecticut |
2 |
80 |
0.03 |
|
South Dakota |
2 |
82 |
0.02 |
|
Texas |
10 |
410 |
0.02 |
|
Indiana |
1 |
42 |
0.02 |
|
Minnesota |
24 |
1,144 |
0.02 |
|
Michigan |
1 |
54 |
0.02 |
|
Colorado |
7 |
418 |
0.02 |
|
Oregon |
1 |
60 |
0.02 |
|
Ohio |
2 |
122 |
0.02 |
|
Rhode Island |
1 |
69 |
0.01 |
|
Hawaii |
1 |
86 |
0.01 |
|
New Mexico |
1 |
129 |
0.01 |
|
Louisiana |
1 |
168 |
0.01 |
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
